1005403-35-9

Basic information

• Product Name: (R)-2-methyl-1-{3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenoxyl]propyl}pyrrolidine
• Synonyms: (R)-2-methyl-1-{3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenoxyl]propyl}pyrrolidine
• CAS NO: 1005403-35-9
• Molecular Weight: 345.29
• Mol File: 1005403-35-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R)-2-methyl-1-{3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenoxyl]propyl}pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-methyl-1-{3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenoxyl]propyl}pyrrolidine(1005403-35-9)
• EPA Substance Registry System: (R)-2-methyl-1-{3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenoxyl]propyl}pyrrolidine(1005403-35-9)

Safety Data

• Hazardous Substances Data: 1005403-35-9(Hazardous Substances Data)

Upstream product

• 957061-13-1 2-[4-(3-bromopropoxy)phenyl]-4,4,5,5-tetramethyl-[1,3,2]-dioxaborolane 
• 41720-98-3 (R)-2-methylpyrrolidine hydrochloride 
• 889865-32-1 2-[4-(3-chloropropoxy)phenyl]-4,4,5,5,-tetramethyl[1,3,2]dioxaborolane 
• 269409-70-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 
• 1382182-62-8 C₁₆H₂₅BO₆S 

Downstream Products

• 1174675-06-9 (R)-2-methyl-1-{3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenoxy]-propyl}-pyrrolidine hydrochloride 
• 1174674-56-6 3-chloro-6-{4-[3-((R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}pyridazine 
• 1005398-61-7 Irdabisant hydrochloride 
• 1005401-17-1 4-methoxy-2-methoxymethyl-5-(4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl)-2H-pyridazin-3-one 
• 1005401-18-2 5-methoxy-2-methoxymethyl-4-(4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl)-2H-pyridazin-3-one 
• 1005402-07-2 5-methoxy-4-(4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl)-2H-pyridazin-3-one 
• 1349798-19-1 C₁₉H₂₄N₂O₂ 
• 1349798-31-7 C₂₄H₂₈N₂O₂ 

Relevant articles and documents

Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists

A novel series of 4-pyridazin-3-one and 5-pyridazin-3-one analogues were designed and synthesized as H3R antagonists. Structure-activity relationship revealed the 5-pyridazin-3-ones 8a and S-methyl 8b had excellent human and rat H3R affinities, and acceptable pharmacokinetic properties. In vivo evaluation of 8a showed potent activity in the rat dipsogenia model and robust wake-promoting activity in the rat EEG/EMG model.

Synthesis and evaluation of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists

6-{4-[3-(R)-2-Methylpyrrolidin-1-yl)propoxy]-phenyl}-2H-pyridazin-3-one 6 (Irdabisant; CEP-26401) was recently reported as a potent H3R antagonist with excellent drug-like properties and in vivo activity that advanced into clinical evaluation. A series of pyridone analogs of 6 was synthesized and evaluated as H3R antagonists. Structure-activity relationships revealed that the 5-pyridone regiomer was optimal for H 3R affinity. N-Methyl 9b showed excellent H3R affinity, acceptable pharmacokinetics and pharmaceutical properties. In vivo evaluation of 9b showed potent activity in the rat dipsogenia model and robust wake-promoting activity in the rat EEG model.